April 2004
Gut;Apr2004 Supplement 3, Vol. 53, pA100
Academic Journal
Availability of cost data for Inflammatory Bowel Disease (IBD) is limited for Great Britain, owing to a single payer provider healthcare system in which patient specific costing information is not collected routinely. Quiescent disease: no change in disease severity or drug treatment during the study period, not requiring immunosuppressants or any specialist investigation during the study period. The management of stable IBD is associated with significant health care costs but disease Hares are accompanied by a two-to threefold increase in 6 month secondary care costs.


Related Articles

  • The Effect of Changes in Treatment Patterns on Drug Expenditure. Gerdtham, U-G.; Johannesson, M.; Gunnarsson, B.; Marcusson, M.; Henriksson, F. // PharmacoEconomics;1998, Vol. 13 Issue 1, p127 

    This paper investigates the effects of changes in drug therapy on drug expenditure in Sweden between 1990 and 1995. Analyses have been carried out for both the aggregate drug expenditure and for drug expenditure according to the main groups of the Anatomical Therapeutic Chemical (ATC)...

  • Systemic lupus erythematosus: a therapeutic challenge for the XXI century. Ugarte-Gil, Manuel; Alarcón, Graciela // Clinical Rheumatology;Apr2014, Vol. 33 Issue 4, p441 

    Despite significant advances in our understanding of the pathogenesis of systemic lupus erythematosus (SLE), there are only a few drugs approved by the regulatory agencies across the world for the treatment of these patients; in fact, many of the compounds subjected to clinical trials have...

  • Analgesic therapy for headache: consumption, appropriateness and costs. Iannazzo, Stefania; Cattaruzza, Maria S.; De Filippis, Sergio; Rossi, Flora; Perata, Edea; Di Rollo, Samanta; Coloprisco, Gabriella; Martelletti, Paolo // Journal of Headache & Pain;Mar2002 Supplement 1, Vol. 4, ps84 

    Headache represents not only an individual disease, but also an important pathology for society because its prevalence in the population is about 50.0%. Its physical, emotional, social and economic impacts are often neglected and it is only recently that headache is being considered in a public...

  • Pharmacogenomics and the Evolution of Healthcare: Is it Time for Cost-Effectiveness Analysis at the Individual Level? Bala, Mohan V.; Zarkin, Gary A. // PharmacoEconomics;2004, Vol. 22 Issue 8, p495 

    The efficacy and toxicity of any given drug can vary substantially from one individual to another. The heterogeneity in individual genetics contributes, in part, to this variability. Pharmacogenomics uses each patient’s individual genetic information to identify the drug with the best...

  • Cost Effectiveness, Quality-Adjusted Life-Years and Supportive Care: Recombinant Human Erythropoietin as a Treatment of Cancer-Associated Anaemia. Cremieux, P-Y.; Finkelstein, S.N.; Berndt, E.R.; Crawford, J.; Slavin, M.B. // PharmacoEconomics;1999, Vol. 16 Issue 5, p459 

    Objective: To measure the cost effectiveness of a supportive care intervention when the no-treatment option is unrealistic in an analysis of recombinant human erythropoietin (epoetin) treatment for anaemic patients with cancer undergoing chemotherapy. Further, to assess whether quality-adjusted...

  • Granulocyte-Colony Stimulating Factor Use and Medical Costs after Initial Adjuvant Chemotherapy in Older Patients with Early-Stage Breast Cancer. Griffiths, Robert I.; Barron, Richard L.; Gleeson, Michelle L.; Danese, Mark D.; O'Hagan, Anthony; Chia, Victoria M.; Legg, Jason C.; Lyman, Gary H. // PharmacoEconomics;2012, Vol. 30 Issue 2, p103 

    Background: Granulocyte-colony stimulating factor (G-CSF) reduces the risk of severe neutropenia associated with chemotherapy, but its cost implications following chemotherapy are unknown. Objective: Our objective was to examine associations between G-CSF use and medical costs after initial...

  • Prescribing costs fall for first time. Baines, Emma // GP: General Practitioner;8/4/2006, p7 

    The article informs that the total cost of prescribing drugs in England has fallen in the year 2005. The year 2005 has become the first year in which the cost of drugs dispensed in England went down. Antihypertensive therapy spending fell by 20 percent in the year 2005 at a saving of £126...

  • The Clinical and Economic Potential of Cyclosporin Drug Interactions. Martin, J.E.; Daoud, A.J.; Schroeder, T.J.; Royfirst, M. // PharmacoEconomics;1999, Vol. 15 Issue 4, p317 

    The introduction of cyclosporin significantly improved solid organ transplantation outcomes. However, the costs associated with immunosuppressive therapy increased from approximately $US1000 to $US2000 per patient per year with azathioprine (AZA) and prednisone to $US5000 to $US8000 per patient...

  • Cost-Utility Analysis of Intravenous Immunoglobulin for the Treatment of Steroid-Refractory Dermatomyositis in Thailand. Bamrungsawad, Naruemon; Chaiyakunapruk, Nathorn; Upakdee, Nilawan; Pratoomsoot, Chayanin; Sruamsiri, Rosarin; Dilokthornsakul, Piyameth // PharmacoEconomics;May2015, Vol. 33 Issue 5, p521 

    Introduction: Intravenous immunoglobulin (IVIG) has been shown to be effective in treating steroid-refractory dermatomyositis (DM). There remains no evidence of its cost-effectiveness in Thailand. Objective: Our objective was to estimate the cost utility of IVIG as a second-line therapy in...


Read the Article


Sign out of this library

Other Topics